Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17012052 | 0.81 | GABRA5 (0.48) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL30898915 | 0.78 | MCL1 (0.40) | GABRA5GABRG2GABRB3GABRA3NUDT1 | |
| SCHEMBL23301902 | 0.77 | GABRA5 (0.48) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL29755761 | 0.77 | GABRA5 (0.48) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL22117010 | 0.77 | GABRG2 (0.48) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL22715747 | 0.77 | GABRG2 (0.45) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL16783083 | 0.77 | AOC3 (0.48) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL22715422 | 0.77 | FOLH1 (0.52) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL29472110 | 0.77 | GABRG2 (0.45) | GABRA5GABRG2GABRB3GABRA3GABRP | |
| SCHEMBL29472138 | 0.77 | FOLH1 (0.52) | GABRA5GABRG2GABRB3GABRA3GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307733-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3307733-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-107849031-B | Mannose derivatives for the treatment of bacterial infections | 沃泰克斯药物股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-10407414-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3293183-B1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20180244658-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2018-08-30 | — | — | US | disclosed |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3307733-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3293183-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd. (GB) | 2018-03-14 | — | — | EP | disclosed |
| US-9890157-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| CN-102264731-A | 1, 2, 4 -oxadiazole derivatives and their therapeutic use | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | GABRA5 674/4885GABRG2 654/4885GABRB3 275/4885 |
| US-10407414-B2 | Mannose derivatives for treating bacterial infections | MANBA, MAN2A1, MPDU1 | GABRA5 3355/4885GABRG2 3583/4885GABRB3 4147/4885 |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | GABRA5 4080/4885GABRG2 4151/4885GABRB3 4175/4885 |
| US-20180244658-A1 | Mannose Derivatives for Treating Bacterial Infections | MANBA, MAN2A1, MPDU1 | GABRA5 3355/4885GABRG2 3583/4885GABRB3 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.